F2G Stock
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
Sign up today and learn more about F2G Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About F2G Stock
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified into chemistry-driven discovery. They have also assembled an experienced development capacity.
Funding History
| September 2002 | $4.3M |
|---|---|
| July 2004 | $5.5M |
| February 2006 | $115K |
| March 2006 | $5.0M |
| August 2008 | $6.3M |
| September 2012 | $30.0M |
| September 2014 | $1.4M |
| June 2016 | $60.0M |
| November 2018 | $24.0M |
| August 2020 | $60.8M |
Management
Chief Executive Officer
Ian Nicholson
Chief Scientific and Development Officer
Tony Kennedy
Chief Operating Officer
Mike Birch
Non Executive Director
Christopher Wright
Non Executive Director
Raj Parekh
Board Member
Naveed Siddiqi
Board Observer
Eric Richman
Chairman of the Board
Richard White
Board Of Director
Maha Katabi
Advisor
George Drusano
Chief Medical Officer
John H. Rex
CFO
Ralf Schmid
Board Of Director
Martin Edwards
Member of the Board of Advisor
Mitchell Kurk
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
